Aqr Capital Management LLC Fennec Pharmaceuticals Inc. Transaction History

Aqr Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$5.96 - $7.85 $77,342 - $101,869	-12,977 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.21 - $8.68 $22,442 - $31,369	-3,614 Reduced 21.78%	12,977 $81,000
Q4 2020 Feb 16, 2021	SELL	$5.99 - $8.55 $30,956 - $44,186	-5,168 Reduced 23.75%	16,591 $124,000
Q3 2020 Nov 16, 2020	BUY	$5.19 - $10.17 $112,929 - $221,289	21,759 New	21,759 $132,000
Q4 2018 Feb 14, 2019	SELL	$5.37 - $8.39 $110,407 - $172,498	-20,560 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$7.84 - $10.83 $34,723 - $47,966	4,429 Added 27.46%	20,560 $169,000
Q2 2018 Aug 14, 2018	BUY	$10.05 - $14.33 $162,116 - $231,157	16,131 New	16,131 $168,000

14.7M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $165M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.